Literature DB >> 27275069

Heparin resistance during pediatric cardiac surgery: An unanticipated challenge for an anesthesiologist.

Mohammad Irfan Akhtar1, Syed Shabbir Ahmed1, Shahid S Sami2.   

Abstract

Entities:  

Year:  2016        PMID: 27275069      PMCID: PMC4874094          DOI: 10.4103/0970-9185.182123

Source DB:  PubMed          Journal:  J Anaesthesiol Clin Pharmacol        ISSN: 0970-9185


× No keyword cloud information.
Sir, A major challenge during cardiac surgery is to prevent thrombosis within the cardiopulmonary bypass (CPB) circuit. The coagulation system of the child and infant has been shown to be substantially different than that of the adult, and thus it requires special attention. The risks of CPB for this age group are inversely proportional to the child's age or weight.[1] Heparin has long been the anticoagulant of choice for initiation and maintenance of CPB because it is effective, inexpensive and can easily be reversed.[2] Heparin resistance is defined as the inability to achieve an activated clotting time (ACT) >300 s after administration of >600 IU/kg heparin. Anti-thrombin III (AT) concentrate if available is a better choice to build AT levels for heparin action as it requires smaller volume of fluid compared with a substantial volume load associated with FFP administration.[3] Direct thrombin inhibitors are actually better inhibitors of CPB-induced anti-coagulation than heparin. Agents other than heparin have been used successfully to anticoagulate pediatric patients for CPB, but experience is scarce. The direct thrombin inhibitors r-hirudin, argatroban, and bivalirudin have all been used for CPB and are likely the best alternatives currently available.[4] A 12-year-old child was scheduled for resection of the subaortic membrane. Baseline ACT was 128 s. After administration of 400 IU/kg of unfractionated heparin for going onto cardiopulmonary bypass, ACT did not rise above the baseline. The possible causes of heparin refractoriness, i.e., expired heparin, extravascular administration and ACT monitoring system malfunction, were ruled out. The patient was given the maximum allowable heparin dose of 600 IU/kg, but ACT increased to 160 s only. The patient was suspected to be having antithrombin III deficiency; hence, four units of fresh frozen plasma were transfused with the addition of 5000 IU of heparin afterward. Finally, ACT was done which increased to 750 s. The patient was put on CPB, and the membrane was resected through aortic root. It was suggested to assess AT III deficiency in the patient to avoid complications in future cardiac surgery, but unfortunately, the child was lost to follow-up; therefore, the diagnosis remained to be confirmed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

Review 1.  Fatalities caused by TRALI.

Authors:  Leslie Holness; Maureen A Knippen; Lois Simmons; Peter A Lachenbruch
Journal:  Transfus Med Rev       Date:  2004-07

Review 2.  Coagulation considerations for infants and children undergoing cardiopulmonary bypass.

Authors:  Michael P Eaton; Ellen M Iannoli
Journal:  Paediatr Anaesth       Date:  2011-01       Impact factor: 2.556

Review 3.  Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass.

Authors:  Alan Finley; Charles Greenberg
Journal:  Anesth Analg       Date:  2013-02-13       Impact factor: 5.108

4.  Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study.

Authors:  F-C Riess; B Poetzsch; K Madlener; E Cramer; K-N Doll; S Doll; D E Lorke; J Kormann; G Mueller-Berghaus
Journal:  Thorac Cardiovasc Surg       Date:  2007-06       Impact factor: 1.827

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.